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In the European Union 60,000 patients are diagnosed annually
with renal-cell carcinoma (RCC) [1]. Synchronous metastases
are present in up to 30% of patients, with multiple sites af-
fected in 95% [2,3]. Since an additional 40% of those undergo-
ing surgery for localised RCC develop metachronous
metastasis, approximately 30,000 patients per year are diag-
nosed with systemic disease, of which an estimated 7000
have non-clear-cell histology.
In a recent population-based analysis, lung metastasis was
most frequent at 45.2%, followed by bone at 29.5%, lymph
nodes at 21.8% and liver at 20.3% [4]. Adrenal, brain and other
locations had a lower frequency. Moreover, it was found that
the proportion of patients with multiple metastatic sites was
higher in young patients, 16% and 49% of which had brain and
bone metastasis, respectively [4].
2. Rationale of metastasectomy
Selecting appropriate treatment modalities for metastatic
RCC remains a challenge. Although objective responses fol-
lowing targeted therapy are frequent, complete remissions
occur in only 1–3% [5–7]. Moreover, it has become evident
that, despite the most effective drugs in first-line treatment,
a ceiling is being reached in median overall survival (OS)
which ranges between 9 and 40 months, depending on clini-
cal risk scores [8]. Therefore, together with the occasional
durable responses achieved with high-dose interleukin-2, re-
moval of all lesions, when technically feasible, provides the
only potentially curative treatment. Traditionally, surgical
resection has been the preferred approach (metastasectomy),
but recent data on stereotactic radiosurgery (SRS) and ablative
techniques indicate that other local non-invasive or less-inva-
sive treatment modalities are a valid alternative to surgery.However, only a minority of patients with mRCC are candi-
dates for metastasectomy. No reliable data exist on the pro-
portion of patients with mRCC who will be eligible for this
approach. It has been estimated that only 25% of patients
with metachronous metastasis are suitable candidates for
resection of metastatic disease [9,10]. For patients with syn-
chronous metastasis a recent study addressed this issue. A
whole-nation study on prevalence and potential resectability
revealed that 154 patients (16.9%) had synchronous lung
metastases [11]. However, only 11 with solitary lesions were
deemed eligible for surgical resection, and only one under-
went metastasectomy. In addition, patient selection for this
approach is difficult because of the heterogeneous course of
metastatic RCC. Metastasis may present at diagnosis or with-
in a year after nephrectomy with curative intent, whereas in
others disease-free intervals of more than 20 years have been
observed with a slow growth of lesions. In few cases sponta-
neous regression of metastases has been documented, lead-
ing to the concepts of immune modulation [12,13].
Currently, prognosis and management of mRCC depend on
a number of clinical factors such as performance status, the
length of the disease-free interval, synchronous or metachro-
nous metastasis, as well as the burden of metastatic disease
and the number and location of sites involved [14]. One of
the most commonly used prognostic models, the Memorial
Sloan Kettering Cancer Center (MSKCC) risk score, uses Kar-
nofsky performance status, time from diagnosis to treatment,
and serum haemoglobin, calcium and lactate dehydrogenase
to categorise patients as being at favourable, intermediate or
poor risk [15]. After the introduction of targeted therapy the
MSKCC risk score remains a valid tool together with the vali-
dated Database Consortium (DCM) model to assess the prog-
nosis of patients with comparable concordances of 0.66–0.65
[8,16,17]. Metastasectomy is associated with survival and
clinical benefit across these various risk groups [10,18]. In asmanlaan
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favourable-risk group improved 5-year survival from 36% to
71%, and in the intermediate-risk group from 0% to 38%.
When adjusting for risk score, a 2.7-fold increased risk of
death remained for patients who did not undergo metastasec-
tomy. Median survival time and 2-year survival rates for low-
risk, intermediate-risk and high-risk patients were 76, 25 and
6 months, respectively, suggesting that only patients with a
favourable and intermediate risk live long enough to be can-
didates for metastasectomy. However, MSKCC and DCM
scores were primarily developed to assess prognosis in
patients receiving systemic therapies. Other clinical factors
which may have prognostic value in metastasectomy are
recognised.
Patients who are not candidates for metastasectomy are
being offered systemic targeted therapy. Following response
or substantial downsizing, metastasectomy is occasionally
reconsidered in selected individuals to achieve complete
resection and even interrupt targeted therapy. This approach
is investigational and has not been prospectively studied, but
case reports and retrospective series have been published.
A case series described three patients after complete
resection of liver, lymph node and vertebral metastases fol-
lowing absence of further progression under treatment with
sorafenib and sunitinib [19]. Patients remained disease-free
after 16, 24 and 29 months.
Targeted therapy has been discontinued after complete
resection of metastatic lesions. A series included six patients
after complete resection of residual metastases in the lungs,
iliac bone, skin and thyroid following treatment with suniti-
nib. The patients remained off treatment for 5–19 months
[20,21]. The largest study included 22 patients receiving
metastasectomy following targeted therapy [22]. Metastasec-
tomy was performed in the retroperitoneum, lung, adrenal,
bowel, mediastinum, bone and brain. Consolidative metasta-
sectomy proved feasible with acceptable morbidity, although
it resulted in a significant time off targeted therapy and
long-term disease-free interval. However, it is not known
whether this was primarily due to the complete resection of
metastatic disease, which has been identified as an indepen-
dent factor associated with prolonged survival, or the combi-
nation of surgery and targeted therapy.
Ultimately, adequate selection for metastasectomy is of
critical importance. If applied appropriately, surgical resec-
tion alone or in combination with targeted agents may result
in outcome that is superior to systemic therapy alone.
3. General prognostic factors of
metastasectomy
The bulk of literature on metastasectomy dates back to the
last century, when it was observed that patients with solitary
resectable metastasis or multiple metastases restricted to one
resectable organ site may have a survival benefit in the
absence of effective systemic therapeutic options. In the
1930s there was a report of a patient who survived 23 years
following pulmonary metastasectomy [23]. In 1978, one of
the first series on metastasectomy in 41 patients with solitary
lesions in the lungs, pleura, central nervous system and
abdomen was published. In patients with complete surgicalresection, the median disease-specific survival was
27 months, with 59% of the patients alive at 3 years [24]. Sev-
eral authors concluded similar 3-year and 5-year survival
after resection of a solitary lesion [25–27] or observed a signif-
icant difference in survival in patients with metachronous
and synchronous metastasis [28–30].
In a series involving 179 patients the 5-year survival rate
after resection of solitary lesions was 22% for synchronous
versus 39% for metachronous metastases [31]. In addition,
multiple clinical trials from the cytokine era revealed a strong
association of outcome and metastatic sites [32,33]. In a retro-
spective analysis of 101 patients with resection of a total of
152 metastatic lesions at different organ sites [34], median
survival was 28 months for the entire series. Survival was im-
proved after resection of lung metastases when compared to
other tumour locations and for patients clinically tumour-free
after metastasectomy. Again, the time interval between pri-
mary tumour resection and metastasectomy correlated posi-
tively with survival.
Others have observed similar differences in 5-year survival
rates for solitary metastases (56% for lungs, 28% for skin, 20%
visceral organs, 18% peripheral bone, 13% brain and 9% axial
bone metastases) [31]. One study evaluated 278 mRCC pa-
tients to define selection criteria for patients with solitary
metastases [35]. On multivariate analysis, factors associated
with a favourable outcome were a solitary site and single
metastasis, complete resection of the first metastasis, a long
disease-free interval and a metachronous presentation. Since
then, multiple retrospective series have been published that
support these favourable factors [32,36,37] (Table 1).
In a recent retrospective analysis of 109 patients who
underwent primary tumour resection and at least one
metastasectomy for mRCC, the following additional factors
were associated with OS [38]; primary tumour stage PT3
stage, Fuhrman grade P3, non-pulmonary metastases, mul-
ti-organ metastases and disease-free interval 612 months
were negative pretreatment prognostic factors with an accu-
racy of 0.87.
As data from Japan suggest, complete metastasectomy is a
favourable prognostic factor independent of race or geograph-
ical location [39]. No data from prospective randomised trials
on metastasectomy for RCC exist, and decision-making relies
on retrospective series. It cannot be excluded that the benefit
of metastasectomy is due largely to a lead-time bias based on
differences in tumour biology. Patients with solitary and
oligometastatic disease and a prolonged metachronous
interval are more likely to undergo metastasectomy, while
those with extensive metastatic burden, rapid progression
and reduced performance will probably never be considered
for resection. Perhaps not surprisingly, one series found
having an aggressive tumour grade to be the only adverse
factor for survival [40].
The significance of tumour heterogeneity and aggressive-
ness should not be underestimated in the interpretation of
data which extend the indication for metastasectomy to
multiple sites with the aim of achieving complete resection.
Complete resection of multiple lesions has been reported as
either a resection performed simultaneously at one or more
sites or as repeat metastasectomy of asynchronous recur-
rences after the first resection.
Table 1 – Factors associated with a favourable outcome after metastasectomy, including sterotactic radiosurgery (SRS).
General and additional reported site-specific factors for the most common sites.
Generala Pulmonary
metastasis
Skeletal
metastasis
Brain metastasis
Solitary or
oligometastatic
lesions
<7 Metastases Peripheral location
of metastases
RPA class I:
1. Karnofsky PS >70%
2. Age<65 years
3. Absence of extracranial metastases
Metachronous
metastasis and
disease-free interval
of >2 years
Absence of
mediastinal lymph-
node metastases
Wide excision After SRS: >75% decrease
of the lesion
Complete resection Metastases <4 cm Clear-cell
subtype
Single-organ site Unilateral lung
involvement
Good performance
status (Karnofsky,
ECOG, WHO)
Munich I: R0, no risk
factor
MSKCC or DCM good
and intermediate risk
Munich II: R0, P1
factor
Absence of
sarcomatoid features
Absence of nodal
metastases
Based on Munich
Score risk factors:
1. Pleural infiltration
2. Synchronous disease
3. Retroperitoneal LN
4. Metastases >3 cm
5. Mediastinal/hilar LN
6. Complete resection
ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; MSKCC, Memorial Sloan Kettering Cancer Center; DCM,
Database Consortium model; LN, lymph node.
a Recommendations for lymph node, liver, adrenal, pancreatic and thyroid metastasis and other less frequent sites follow the general factors.
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nign course of the disease. In selected cases repeat metasta-
sectomy results in exceptionally long survival lasting more
than 10 years [41,42]. In a relatively large study of 141 patients
with complete resection of solitary metastases, 5-year sur-
vival rates after complete resection of second and third
metastases were no different when compared to those of
the first metastectomy (46% and 44%, respectively, versus a
43% 5-year OS rate) [35]. This supports data from an early ret-
rospective study on repeat metastasectomy which led to im-
proved survival compared to non-surgical treatment of
recurrence after first metastasectomy [43].
Recently a large study analysed survival of patients after
complete metastasectomy for multiple synchronous metasta-
ses at one or more sites [9]. Of 887 mRCC patients, 125 were
identified who underwent complete surgical resection of mul-
tiple metastases (two to three or more metastases); 52% had
resection at two or more sites, including lungs, bone, viscera
and other locations. Patients with multiple non-lung-only
metastases had a 5-year survival rate of 32.5% with complete
resection versus 12.4% without. After controlling for perfor-
mance status and disease burden, an almost threefold in-
creased risk of death remained for patients with incomplete
resection. A scoring algorithm from the same institution to
predict survival for patients with clear-cell mRCC suggests
that complete resection of multiple metastases was associ-
ated with a 50% decrease in the risk of death [14]. It cannotbe ruled out that multiple metastasectomy benefited those
patients who would have had a favourable course of disease
regardless of surgical intervention. Collectively, these data
underscore that careful selection of patients with multiple
RCC metastases should be made according to the general
prognostic factors (Table 1).
A prominent feature of RCC is its ability to metastasise to any
anatomical location. Generally, there is little information on
how to treat rare sites. In these circumstances factors associ-
ated with a favourable outcome after metastasectomy at more
frequent sites should be considered for treatment selection
(Table 1). Individual decisions have to be taken for each case.
However, certain metastatic sites are consistent and more
frequently observed. This has led to additional information
that may guide treatment decisions. Specific management
strategies for the most frequent sites will be discussed in de-
tail. In contrast to traditional surgical metastasectomy, ste-
reotactic radiosurgery (SRS) or ablative techniques have
been largely applied to certain metastatic sites [44]. Although
treatment of RCC metastases with SRS is gaining ground and
is likely to be expanded to multiple anatomical regions, most
of the experience stems from brain and bone metastasis and
will be discussed below. While ablative techniques are mini-
mally invasive and can cause bleeding and thermal damage,
cranial and extracranial SRS involves adverse events such as
cough, fatigue, skin rash and local pain. Side effects are gen-
erally frequent, but mild (grades I–II in 96%) [45].
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4.1. Lymph-node metastases
Data on nodal metastasectomy are difficult to interpret. They
are not regarded as distant metastasis (M) in the tumour-
node-metastasis (TNM) classification, and often occur in
association with further systemic metastatic sites. As a con-
sequence nodal metastasis can manifest as different disease
stages and is generally associated with a poor outcome that
resembles that of systemic disease in retrospective series
[46]. In few studies are locoregional and distant (mostly medi-
astinal) lymph-node metastases differentiated. There is evi-
dence that resection of isolated nodes may be beneficial in
terms of survival.
In fact, isolated lymph-node metastasis is rare. Between
58% and 95% of patients with lymph-node involvement have
associated hematogenous metastases [47,48]. Patients with
pathological N0 have a 5-year OS of 75%, versus 20% for pa-
tients with lymph-node metastases [46,49]. Despite this, pa-
tients with single lymph-node metastases and no
metastatic disease can potentially be cured by lymph-node
dissection (LND) [49].
Regional lymph-node metastases in RCC range from 13%
to over 30%. However, the true incidence of solitary nodal
metastasis without further systemic disease is unknown. In
nephrectomy and autopsy studies single nodal metastases
were observed in smaller tumours in 3–4.5% [46,49,50]. At au-
topsy, anatomical location of lymph-node metastases was
unpredictable [51]. The authors found ipsilateral renal hilar
lymph-node metastases in 7%, pulmonary hilar lymph-node
metastases in 66.2%, retroperitoneal in 36%, para-aortal in
26.8% and supraclavicular in 20.7% [51]. In addition, single
metastases in mediastinal, axillary, supraclavicular and iliac
lymph nodes without any further metastasis were described
[52,53].
In node-positive cases lymph-node dissection was associ-
ated with improved survival and a trend towards an improved
response to immunotherapy [49]. Patients with regional nodes
and distant metastases had significantly inferior survival to
those with either condition alone. However, lymph-node sta-
tus had less impact on survival than primary tumour stage,
grade and performance status. [49]. Current guidelines advise
that suspicious lymph nodes either at imaging or on palpation
should be removed during nephrectomy because LND for clin-
ically positive lymph nodes is associated with improved sur-
vival when performed in carefully selected patients [49].
A recent systemic review of the available literature con-
cluded that data from the majority of retrospective non-ran-
domised studies suggest that a possible benefit in terms of
OS exists for patients with node-positive disease [54]. In addi-
tion, LND at the time of nephrectomy may avoid symptomatic
local recurrences. As most clinically suspicious lymph nodes
are removed at the time of nephrectomy, few data exist on the
management of metachronous regional lymph-node metas-
tases and are often summarised in series reporting on local
recurrences [55], but there is a tendency to choose an investi-
gational approach and pre-treat these lesions prior to surgical
removal.Several cases have been reported with downsizing of nodal
metastases following tyrosine kinase inhibitors. Subsequent
to sunitinib therapy, complete resection of bulky lymph nodes
with encasement of the great vessels not amenable to initial
excision was performed in a number of patients with clear-
cell histology and no evidence of further lesions [56–59].
Downsizing up to 40% was reported following 5–10 cycles.
‘Second-look’ surgery with complete retroperitoneal LND
was feasible in all cases. Despite necrosis, viable clear-cell
carcinoma was present in all cases.
4.2. Thoracic metastases
Pulmonary, pleural and mediastinal lymph-node metastases
occur frequently in RCC and are found simultaneously in
20–35% of patients [60–62]. Lung lesions are most frequent
and have a prevalence rate of 74% in autopsy studies [51].
Metastasis is mostly hematogenous, but direct lymphatic
drainage from the kidney into the thoracic duct which subse-
quently drains into the subclavian vein and pulmonary artery
has been proposed [63].
There are many retrospective series on resection of pul-
monary metastases, but most of the earlier studies were
small [33,35,64–67]. Collectively, recent series with larger pa-
tient cohorts observed a 5-year survival rate of 37–54% pro-
vided that complete resection of solitary or oligometastatic
pulmonary metastases was achieved [9,35,60–62,68–74]. Con-
sistent and robust prognostic factors were identified in multi-
variate analyses (Table 1). Incomplete resection was
associated with a poorer 5-year survival of 0–22%
[9,35,60,62,71,74,75], as was the number of pulmonary metas-
tases removed [9,35,62,68,69,75]. Thus, median 5-year survival
after complete resection of a solitary lesion was 45.6–
49 months versus 19–27 months after complete resection of
multiple metastases [68,69,75].
In a large study a significantly longer median 5-year sur-
vival was observed for patients with fewer than seven pul-
monary metastases versus those with more than seven
metastases (46.8% versus 14.5%) [62]. Furthermore, the pres-
ence of lymph-node metastasis was associated with shorter
survival [60–62,74].
Despite complete pulmonary metastasectomy, mediasti-
nal lymph-node metastases decreased median survival from
102 months to 19 months [60] and the median 5-year survival
rate from 42.1% to 24.4% [62]. A short disease-free interval
after nephrectomy or the presence of synchronous metastasis
had a poor outcome [35,62,69,71,74,75]. Disease-free interval
of > or <48 months or 23 months were associated with a med-
ian 5-year survival rate of 46% versus 26% (69) and 47% versus
24.7%, respectively [62]. The presence of synchronous pul-
monary metastasis had a particularly poor outcome, with a
median 5-year survival rate after complete pulmonary metas-
tasectomy of 0% versus 43% for patients with metachronous
disease [75].
Size of pulmonary metastasis is an additional factor
[61,74,76].A median 5-year survival rate of 70% versus 35%
was observed after complete resection of metastases either
< or >0.5 cm [76]. In an attempt to define a prognostic score,
200 consecutive patients with pulmonary metastases were re-
cently evaluated in a single centre [77]. By multivariate anal-
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tive lymph-node status of the primary tumour, synchronous
metastases, pleural invasion and hilar or mediastinal
lymph-node metastases were independent prognostic fac-
tors. From these factors the Munich score was developed
which discriminates three risk groups with median OS of
90, 31 and 14 months for low, intermediate and high risk,
respectively (Table 1).
However, some investigators have found no association
with the type of resection and survival [68,73]. SRS or ablative
techniques may be an alternative to surgical resection in se-
lected patients [45,78]. In a prospective phase II trial of extra-
cranial SRS given to 82 metastases in mRCC, a total of 63 lung
lesions were treated [45]; 50% of the patients were MSKCC
favourable-risk and 46.7% intermediate-risk. In 21% of the
treated sites total regression was observed after 3–36 months,
while another 31% showed regression of >50% after 3–
12 months. Median OS was 32 months, suggesting that con-
trol and outcome can be achieved similarly to surgical metas-
tasectomy. A recent retrospective analysis including 39 lung
lesions suggests that a single fraction equivalent dose (SFED)
of P45 Gy is effective for controlling RCC metastases [79].
Isolated mediastinal lymph-node metastasis without pul-
monary or other lesions is frequently observed in RCC [80–
82]. This may be a consequence of renal lymphatic vessels
which always connect to the origin of the thoracic duct, some
directly without traversing any retroperitoneal nodes [63].
Resection of isolated mediastinal and intrapulmonary nodal
metastases has resulted in DFS of up to 5 years [83,84]. As
these lymph nodes are usually not resected at the time of
nephrectomy, these series contain mostly metachronous no-
dal metastases. As already mentioned, concurrent mediasti-
nal lymph-node and lung metastases have a poorer
prognosis [60–62]. These studies provide information on the
potential prevalence of lymph-node metastases in patients
with pulmonary metastatic disease which was 20–35%. With
a median OS of <2 years, patients with pulmonary metastases
and mediastinal lymph nodes may not be candidates for sur-
gical resection, though match paired analysis suggests a
trend towards improved survival [60].
4.3. Bone
Bone metastases occur in 16–26% of patients with metastatic
RCC and are often symptomatic [15]. The prevalence of soli-
tary bone metastasis may be low. In a series of 94 patients
with solitary metastasis, single skeletal secondaries were ob-
served in five patients (5.3%) [35]. Another retrospective series
reported a rate of 2.5% [25]. Although prolonged disease-free
survival has been reported after surgical resection of single
and even multiple bone metastases, the most frequent indi-
cation for treatment are symptoms such as pain from
nerve-root compression and pathological fractures. Exter-
nal-beam radiotherapy may be equally effective, but no ran-
domised data exist specifically for RCC. As for other
metastatic sites, outcome after surgical resection of skeletal
solitary or oligometastases has only been evaluated retro-
spectively. Early reports suggested that patients with solitary
bone lesions have a better survival after resection [85]. In a
small study analysing bone metastasis from RCC in 13 evalu-able patients with solitary lesions, a 5-year survival rate of
55% for the entire cohort was achieved [86].
The 5-year OS rate after resection of solitary bone lesions
in other series was 40% [35] and 54%, respectively [87],
although numbers were very small. Conversely, a series
including 25 patients reported a 5-year survival rate of only
13%, despite wide resection of solitary bone metastasis [88].
A recent series evaluated 125 patients after resection of multi-
ple metastases, including 11 with bone as single site (8.8%)
and four (3.2%) with bone and lung involved [9]. The majority
(75.2%) had more than three metastases removed. For pa-
tients with extrapulmonary sites the 5-year OS rate was
32.5% when complete resection was achieved compared with
12.4% among a matched cohort without complete resection.
One of the largest studies on resection of RCC bone metas-
tases included a literature review. Five-year survival rates
were 35.8–55%, comparable to OS observed after resection of
lung lesions [86]. Patients with peripheral skeletal location
of metastases had a 75% 5-year survival rate. Collectively,
metachronous disease with a long disease-free interval,
peripheral skeletal location with wide excision and solitary
metastases were correlated with longer survival [86]. A fur-
ther prognostic factor is the presence of a clear-cell histolog-
ical subtype. Interestingly, the additional presence of
pulmonary metastases did not predict early death, some pa-
tients surviving for years after complete resection of pulmon-
ary and bone disease [9,89].
Similar predictive factors and survival rates were reported
in a number of smaller retrospective series [87,88,90,91]. Be-
cause of the retrospective data evaluation, the impact on out-
come of resection of RCC bone lesions remains controversial.
However, surgical resection of bone lesions to effectively
palliate pain and symptoms from spinal cord compression
is undisputed.
A randomised prospective trial in patients with bone
metastasis from various malignancies, including RCC,
demonstrated that immediate decompressive surgery and
postoperative radiotherapy are superior to treatment with
radiotherapy alone for patients with spinal cord compression
[92]. In addition, a prospective non-randomised study demon-
strated that spinal surgery was effective in improving quality
of life in patients with extradural spinal metastases from var-
ious cancers by providing better pain control, enabling pa-
tients to regain or maintain mobility, and offering improved
sphincter control [93]. Surgery resulted in acceptably low mor-
tality and morbidity rates.
RCC bone metastases are highly destructive vascularised
lesions. The risk of life-threatening haemorrhage poses a seri-
ous surgical challenge. The largest retrospective study on sur-
gical approach and outcome included a total of 368 RCC bone
metastases to the limbs and pelvis [89]. Surgical procedures
involved curettage with cementing and/or internal fixation,
en-bloc resection with closed nailing or amputation. The
1-and 5-year OS rates were 47% and 11%, respectively. How-
ever, 15 patients (5%) died within 4 weeks after surgery due
to acute pulmonary or multi-organ failure.
Regarding palliation, resection of painful RCC bone metas-
tases relieved pain significantly in 91% of patients. A good to
excellent functional outcome was achieved in 89%, and 94%
with metastatic lesions of the pelvic girdle and lower extrem-
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recurrence at the same location and the need for re-interven-
tion [94]. This was a general observation made in bone metas-
tasis from a variety of cancers where wide excision resulted in
improved survival and functional outcome compared to lam-
inectomy alone [93].
Surgery for bone lesions should therefore aim at lasting
control at the treated site with a durable fixation or
reconstruction to prevent re-intervention. As the only ran-
domised trial performed included radiotherapy in both arms,
postoperative radiotherapy is advised [92].
Ablative approaches may be an alternative to surgery in
selected cases with bulky bone lesions extending to extra-
osseous regions [95,96]. As with other extracranial locations,
SRS for spinal metastasis of RCC has been shown to be effec-
tive in a series of 48 patients with 55 spinal lesions [97]. The 1-
year absence of progression rate in the spine was 82.1%. This
early series suggests that SRS to spinal metastases is effective
in palliating symptoms. At baseline, 23% of patients were
pain-free, and this increased to 44% 1 month and 52%
12 months after SRS. In a retrospective study of 24 painful
RCC bone lesions a relationship between dose and stable pain
relief was observed in patients treated with a dose of 40 Gy in
five fractions [98]. Adverse events were absent except one
grade 1 skin toxicity. These data suggest that symptomatic
and painful RCC skeletal metastases at various anatomical
sites can be effectively controlled and palliated by SRS, and
prospective non-randomised trials have been initiated.
5. Intra-abdominal organ metastases
5.1. Liver
Hepatic metastases are diagnosed in 8–30% of patients with
RCC [15]. An autopsy study reported liver metastasis from
RCC in 41% [51]. Only in 5% were these metastases solitary
metachronous lesion [99]. The simultaneous presence of mul-
tiple organ sites explains the paucity of reports on liver
metastasectomy either by surgery or by ablative techniques
[100]. In addition, in contrast to solitary pulmonary metasta-
ses, liver metastases are consistently associated with a poor
prognosis [31,32,34].
A few retrospective series with 13–68 patients suggest that
surgical resection may be beneficial in terms of survival
[99,101–104]. Earlier series reported a median survival follow-
ing resection of solitary liver metastasis of 16–48 months with
5-year survival rates of 8–38.9% [99,101,102,104]. Factors asso-
ciated with a good prognosis were disease-free interval longer
than 6–24 months, performance status and completeness of
resection. A large retrospective series analysed the outcome
of 88 patients with liver as the only metastatic site [103].
Sixty-eight patients underwent metastasectomy compared
to 20 who refused. The median 5-year OS rate after metasta-
sectomy was 62.2% versus 29.3% in the control. In both
cohorts 79% received systemic therapy, which suggests that
liver metastasectomy may be appropriate for carefully
selected patients. Patients with high-grade RCC and synchro-
nous metastases did not benefit from hepatic metastasecto-
my. Furthermore, metastasectomy is associated with
significant morbidity of 20.1% [103]. One series even reporteda mortality rate of 31% [99]. In contrast, a contemporary mul-
ti-institutional analysis of 43 patients reported a low morbid-
ity and near-zero mortality [105]. Three-year OS was 62.1%
with a median recurrence-free survival of 15.5 months. How-
ever, recurrence occurs in up to 50% after liver resection
[101,105]. Morbidity, mortality and recurrence need to be bal-
anced against a potential benefit when selecting patients. It
may be that surgery of small lesions is not superior to the
use of ablative techniques in this setting which have been ap-
plied effectively [106]. SRS has been applied in a few patients
with liver metastasis.
In a Swedish single-centre prospective study including
multiple sites three liver lesions were treated successfully
[45]. A retrospective analysis of SRS to RCC and melanoma
metastases revealed that liver lesions treated with SRS with
a SFED of P45 Gy had a local control rate at 24 months of
100% [79].
5.2. Adrenal metastases
Adrenal metastasis has been found in 3.1–5.7% in nephrec-
tomy series [107–109]. In up to 23% of adrenal lesions simulta-
neous metastasis at other sites were present. Adrenal
metastasis generally has a poor prognosis despite complete
resection of solitary ipsilateral metastases at the time of
nephrectomy. It is unknown whether this is directly due to
the adrenal involvement or a consequence of an often con-
comitant advanced locoregional tumour stage. In 347 patients
with advanced stage disease (T3-4N0-1M0-1) adrenal metas-
tases occurred in 8.1% [109]. Among 56 patients with adrenal
metastases, 82% had pT3 tumours [108]. Presence of distant
metastases, vascular invasion within the primary tumour
and multifocal growth of renal-cell cancer within the tu-
mour-bearing kidney were identified as independent predic-
tors of adrenal metastases [110].
The majority of radiographically or clinically apparent
ipsilateral adrenal metastases are resected at the time of
nephrectomy. Isolated, synchronous contralateral and
metachronous ipsilateral or contralateral adrenal metastases
are rare, and little is known about their management. They
are often included in series on the management of local
recurrences [55,111,112]. Survival with locally recurrent re-
nal-cell carcinoma is poor, with a 5-year survival rate of 28%
[111]. Patients after surgical resection had an improved 5-year
survival rate of 51% compared to 18% treated with systemic
therapy and 13% with observation alone.
Contralateral adrenal involvement, either synchronous
or metachronous, is rare. In one autopsy series of patients
after nephrectomy for RCC it was observed in 0.7% [51]. A
small series on the outcome of 11 patients after surgery
for metastatic RCC in the contralateral adrenal gland re-
ported that synchronous contralateral adrenal metastasis
occurred in two patients. The mean (median, range) time
to contralateral adrenal metastasis after nephrectomy for
nine patients was 5.2 (6.1, 0.8–9.2) years. All patients had
adrenalectomy. Despite resection, most patients in this
study died from RCC after a median of 3.7 (range 0.2–
10) years after adrenalectomy for contralateral adrenal
metastasis [113]. Collectively, not more than 60 cases are de-
scribed in the literature [114–116]. Survival ranges from 8 to
198 E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 9 2 –2 0 370 months, and factors associated with outcome are uncer-
tain. Some observed an association of survival with a
metachronous interval of >18 months [115]. In summary,
adrenalectomy for isolated metachronous ipsilateral and
contralateral adrenal metastasis is recommended because
it is associated with long-term survival in individual pa-
tients. Ablative percutaneous techniques may be an alterna-
tive to open or laparoscopic adrenalectomy [117].
5.3. Pancreatic metastases
Pancreatic metastases of RCC are relatively infrequent but have
been described in 411 patients in 170 publications [118]. A sys-
tematic literature search reported the clinical outcome of pan-
creatic RCC metastases [118]. Of the metastases, 321 were
treated surgically and 73 non-surgically. In the metastasectomy
group 65.3% of the lesions were solitary and symptomatic in
57.4%. Following metastasectomy, 2-year and 5-year disease-
free survival was 76% and 57%, respectively. Interestingly, the
2- and 5-year OS rates were 80.6% and 72.6%. Further extrapan-
creatic disease had no impact on OS in the metastasectomy
group. Surprisingly, the time to pancreatic metastasis and the
number of pancreatic lesions were not associated with a worse
outcome. As expected, patients with unresected pancreatic dis-
ease had a significantly shorter 2- and 5-year overall survival
rate of 41% and 14%, respectively. These data suggest that
metastasectomy may be beneficial in patients in whom the pan-
creas is the only metastatic site and who are fit enough to under-
go pancreatic surgery. In-hospital mortality after pancreatic
metastasectomy was 2.8%, and a significant number of patients
underwent extensive surgery (pancreaticoduodenectomy in
35.8% and total pancreatectomy in 19.9%). In view of the retro-
spective quality of the data and the significant surgical morbid-
ity, patients with a short time to pancreatic metastasis following
nephrectomy may be best treated with systemic therapy first.5.4. Brain metastases
Brain metastasis is observed in 2–17% of patients with RCC,
and is readily diagnosed by symptoms in more than 80% of
cases [119–121]. If left untreated, median survival is poor
(3.2 months) [122]. After the introduction of SRT, indications
for craniotomy have been largely abandoned except for lesions
>2–3 cm, rapid onset of symptoms and in cases of large lesions
with midline shift [123–125]. Because of their relative paucity,
therapeutic strategies for RCC brain metastases have often
been evaluated together with cerebral lesions of various pri-
mary tumours. Generally, selection of patients for therapy of
brain metastases, regardless of the primary tumour site,
involves assessment of performance status, extracranial
tumour load and the course of the disease, as summarised in
the Radiation Therapy Oncology Group (RTOG) recursive parti-
tion analysis (RPA) [126]. Unfortunately, the majority (70–80%)
of patients with RCC brain lesions belong to RPA class II – Kar-
nofsky score (KS) >70%, further extracranial metastases – who
have a poor median survival of 4.2 months [124,127].
In another study, including 4295 patients, significant prog-
nostic factors for RCC brain metastasis were KS performance
status and number of brain metastases [128]. Those with a KS
of 90–100% and a single brain metastasis had a median OS of14.8 months versus 3.3 months for those with a KS <70% and
more than three metastases. Others have confirmed these
observations [125].
An early retrospective series of whole-brain radiation ther-
apy (WBRT) observed survival of patients with single brain
metastases from RCC of 4.4 months only, which suggested that
aggressive surgical treatment would be superior [129]. A pro-
spective randomised trial of surgery and WBRT versus WBRT
alone was in favour of the combination, although only few of
the 63 patients with brain metastases had RCC [130,131].
For patients with extracranial progressive disease WBRT
seemed sufficient. In a further study, craniotomy with resection
of brain metastases in 50 patients with RCC again proved supe-
rior to WBRT, with a median overall survival of 12.6 months
[132]. However, the addition of postoperative WBRT did not
result in a survival difference. Currently, WBRT is regarded an
adequate choice for patients with a poor performance and
multiple lesions in whom palliative control of symptoms is
the principal aim. In contrast to WBRT, SRS can provide effec-
tive local control comparable to surgery, even when multiple
lesions and recurrent metastases are present [133].
Experience with SRS in the treatment of brain lesions ex-
ceeds that at extracranial sites. This is because SRS has been ap-
plied relatively early after its introduction to brain metastases
as ‘gamma knife’ or ‘radiosurgery’ with the first series on RCC
published in 1998 [134]. In one of the larger series, 85 patients
with 376 brain metastases from RCC underwent SRS [124].
The median tumour volume was 1.2 cm (range: 0.1–14.2 cm)
although 65% had multiple brain lesions. Median OS was
11.1 months after SRS with a local tumour control rate of 94%.
Most patients (78%) died because of systemic progression. RTOG
RPA classes I, II and III survived for 24.2 months, 9.2 months and
7.5 months, respectively. Another SRS series of 69 patients ob-
served a median survival of 13 months in patients without
and 5 months in those with active extracranial disease [135].
In a recent retrospective analysis 46 patients with 99 brain
lesions were treated by SRS [136]. A single brain metastasis
was treated in 56.5%. Local tumour control was achieved in
84.7%. Median OS was 10 months, but increased to 18 months
for those with a >75% decrease in metastasis volume. It has
been argued that survival rates after SRS are inferior to those
after craniotomy, but the size of the retrospective series
involving patients with RCC brain metastases, and the fact
that more patients with a long metachronous interval and
fewer brain metastases were candidates for craniotomy
[132,137], do not allow a direct comparison.
5.5. Thyroid metastases
The thyroid gland is infrequently involved, and the first cases
were reported in the 1940s [138]. The largest retrospective study
evaluated 45 resections of solitary thyroid metastases at 15 dif-
ferent centres [139]. The 5-year overall survival rate was 51%.
Prognosis was significantly poorer in patients >70 years of age,
but no other factors were established. There was a striking coin-
cidence of thyroid and pancreatic metastases (31%).
Another group reported on seven patients with solitary
RCC metastases in the thyroid and a median OS after thyroid-
ectomy of 38.1 months [140]. In a clinicopathological study of
36 cases, 64% had documented previous evidence of RCC as
Table 2 – Median overall survival and 5-year survival rates after surgical complete resection or stereotactic radiosurgery (SRS)
of solitary or oligo metastasis at various sites.
Metastatic site Patient numbers Median OS 5-Year survival rates (%)
Pulmonary 48–200 Munich I: 90 months
Munich II: 31 months
Munich III: 14 months
After SRS: 32 monthsa
37.2–54
Liver 31–68 Not reported 38.9–62.2
Bone 9–38 Not reported 40–55
Brain 11–138 RPA I: 14.8 months
RPA II: 4.2 months
After SRS:
RPA I: 24.2 months
RPA II: 9.2 months
12–18
Adrenal (ipsi- and contralateral) 5–30 8–70 months 51–100
Pancreas 321 (review) Not reported 57
Thyroid 7–45 38.1 months 51
RPA, recursive partition analysis.
a 97% Memorial Sloan Kettering Cancer Center (MSKCC) favourable and intermediate.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 1 9 2 –2 0 3 199long as 21.8 years before the thyroid lesion developed (mean,
9.4 years). After a mean follow-up of 9.1 years, 36% were alive
or had died without evidence of disease [141].
6. Conclusion
Only few and selected patients, especially those with solitary
metastases at single-organ sites, may benefit from metasta-
sectomy. Consistently, survival benefit and even cure have
been reported after complete surgical resection and SRS (Ta-
ble 2). However, available data specifically related to RCC are
from retrospective non-randomised studies. Therefore it re-
mains unresolved whether the observed survival benefit is a
consequence of surgical intervention or a selection of pa-
tients with more benign tumour biology who, owing to a mild
clinical course, were considered for metastasectomy.
The best outcome has been observed after resection of
metachronous solitary or oligometastases in the lung, but
similar survival rates were reported for other sites, including
liver, pancreas, bone and even multiple sites, provided that
complete resection was achieved.
Despite consistent prognostic factors associated with a
favourable outcome following metastasectomy, no general
therapeutic guideline can be given. Careful patient selection
is paramount, and the decision to resect metastases has to
be taken for each site and each individual patient. Perfor-
mance status, risk profiles, patient preference and alternative
techniques to achieve local control, such as SRS or ablation,
will have to be considered. After the introduction of targeted
therapy, more patients with metastatic RCC may become can-
didates for complete surgical resection; pretreatment and
multimodality concepts integrating medical and surgical
treatments are being investigated.7. Conflict of interest statements
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